Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

$50m Series C fundraising helps spend optimisation platform Vertice solve procurement’s challenges with automation, benchmarking and intelligent workflows On a mission to simplify procurement, Vertice ...

Vertex's total revenues for Q4 2024 were $178.5 million, marking a 15.2% increase year-over-year. How much did Vertex invest in research and development for 2025? Vertex plans to invest ...

The end of the Vertex-Verve collaboration comes as investors are reevaluating once sky-high expectations for the gene editing industry as commercial realities set in. Shares of Verve and top companies ...

"And it could be so much more," he said. To that end, Florida Tech has relaunched the underutilized Center for Advanced Manufacturing and Innovative Design as Vertex, a new "applied innovation hub." ...